Literature DB >> 26358312

Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".

Oscar Arrieta1, Laura-Alejandra Ramírez-Tirado2, Renata Báez-Saldaña3, Omar Peña-Curiel2, Giovanny Soca-Chafre2, Eleazar-Omar Macedo-Perez4.   

Abstract

OBJECTIVE: Sixteen percent of US population is Hispanic, mostly Mexican. Recently, two independent American reports demonstrated a higher overall survival (OS) in Hispanic populations compared with non-Hispanic-white populations (NHW) with non-small-cell lung cancer (NSCLC), even when most Hispanic patients are diagnosed at advanced disease stages and have lower income status. We analyzed the clinical, pathological, and molecular characteristics as well as outcomes in a cohort of NSCLC Hispanic patients from the National Cancer Institute of Mexico that could explain this "Hispanic Paradox".
MATERIAL AND METHODS: A cohort of 1260 consecutive NSCLC patients treated at the National Cancer Institute of Mexico from 2007 to 2014 was analyzed. Their clinical-pathological characteristics, the presence of EGFR and KRAS mutations and the prognosis were evaluated.
RESULTS: Patients presented with disease stages II, IIIa, IIIb and IV at rates of 0.6, 4.8, 18.4 and 76.3%, respectively. NSCLC was associated with smoking in only 56.5% of the patients (76.7% of male vs. 33.0% of female patients). Wood smoke exposure (WSE) was associated with 37.2% of the cases (27.3% in men vs. 48.8% in women). The frequency of EGFR mutations was 27.0% (18.5% in males vs. 36.9% in females, p<0.001) and the frequency for KRAS mutations was 10.5% (10.3% men vs. 10.1% in women p=0.939). The median OS for all patients was 23.0 [95% CI 19.4-26.2], whereas for patients at stage IV, it was 18.5 months [95% CI 15.2-21.8]. The independent factors associated with the OS were the ECOG, disease stage, EGFR and KRAS mutation status.
CONCLUSION: The high frequency of EGFR mutations and low frequency of KRAS mutations in Hispanic populations and different prevalence in lung cancer-related-developing risk factors compared with Caucasian populations, such as the lower frequency of smoking exposure and higher WSE, particularly in women, might explain the prognosis differences between foreign-born-Hispanics, US-born-Hispanics and NHWs.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Carcinoma; Gene expression; Hispanic Americans; Human; KRAS Protein; Mutation; Non-Small-Cell Lung; erbB-1

Mesh:

Substances:

Year:  2015        PMID: 26358312     DOI: 10.1016/j.lungcan.2015.08.010

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  19 in total

1.  Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Authors:  Andrés F Cardona; Oscar Arrieta; Martín Ignacio Zapata; Leonardo Rojas; Beatriz Wills; Noemí Reguart; Niki Karachaliou; Hernán Carranza; Carlos Vargas; Jorge Otero; Pilar Archila; Claudio Martín; Luis Corrales; Mauricio Cuello; Carlos Ortiz; Luis E Pino; Rafael Rosell; Zyanya Lucia Zatarain-Barrón
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

2.  Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.

Authors:  Oscar Arrieta; Feliciano Barrón; Laura Alejandra Ramírez-Tirado; Zyanya Lucia Zatarain-Barrón; Andrés F Cardona; Diego Díaz-García; Masao Yamamoto Ramos; Beatriz Mota-Vega; Amir Carmona; Marco Polo Peralta Álvarez; Yolanda Bautista; Fernando Aldaco; Raquel Gerson; Christian Rolfo; Rafael Rosell
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

3.  Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.

Authors:  Lorraine Pelosof; Chul Ahn; Ang Gao; Leora Horn; Alejandra Madrigales; Joan Cox; Dauphne McGavic; John D Minna; Adi F Gazdar; Joan Schiller
Journal:  J Natl Cancer Inst       Date:  2017-01-28       Impact factor: 13.506

4.  Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer.

Authors:  Saé Muñiz-Hernández; Sara Huerta-Yepez; Norma Hernández-Pedro; Laura-Alejandra Ramírez-Tirado; Alejandro Aviles-Salas; Altagracia Maldonado; Daniel Hernández-Cueto; Guillermina Baay-Guzmán; Oscar Arrieta
Journal:  Int J Clin Oncol       Date:  2016-06-15       Impact factor: 3.402

5.  Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer.

Authors:  Alejandro Avilés-Salas; Saé Muñiz-Hernández; Héctor Aquiles Maldonado-Martínez; José G Chanona-Vilchis; Laura-Alejandra Ramírez-Tirado; Norma HernáNdez-Pedro; Rita Dorantes-Heredia; José Manuel RuíZ-Morales; Daniel Motola-Kuba; Oscar Arrieta
Journal:  Oncol Lett       Date:  2016-12-16       Impact factor: 2.967

6.  Hypothesized Explanations for the Observed Lung Cancer Survival Benefit Among Hispanics/Latinos in the United States.

Authors:  Emily Miao; Madelyn Klugman; Thomas Rohan; H Dean Hosgood
Journal:  J Racial Ethn Health Disparities       Date:  2022-05-06

7.  Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.

Authors:  Oscar Arrieta; Graciela Cruz-Rico; Enrique Soto-Perez-de-Celis; Laura-Alejandra Ramírez-Tirado; Enrique Caballe-Perez; Jorge-Negueb Martínez-Hernández; Ivan Martinez-Alvarez; Giovanny Soca-Chafre; Eleazar Omar Macedo-Pérez; Horacio Astudillo-de la Vega
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

8.  Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.

Authors:  Feliciano Barrón; Andrés F Cardona; Luis Corrales; Laura-Alejandra Ramirez-Tirado; Enrique Caballe-Perez; Gisela Sanchez; Diana Flores-Estrada; Zyanya Lucia Zatarain-Barrón; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 9.  Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer.

Authors:  Mario Orozco-Morales; Giovanny Soca-Chafre; Pedro Barrios-Bernal; Norma Hernández-Pedro; Oscar Arrieta
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

10.  Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.

Authors:  Graciela Cruz-Rico; Alejandro Avilés-Salas; Xitlally Popa-Navarro; Luis Lara-Mejía; Rodrigo Catalán; Roberto Sánchez-Reyes; Dennis López-Sánchez; Luis Cabrera-Miranda; Héctor Aquiles Maldonado-Martínez; Suraj Samtani-Bassarmal; Oscar Arrieta
Journal:  Pathol Oncol Res       Date:  2021-04-08       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.